Research map: Real-World Feasibility Assessment of Short-Course Preoperative Endocrine Therapy Using the Ki67 Biomarker in an Australian Cohort of Patients With Estrogen Receptor–Positive Early Breast Cancer

Back to the article

Papers in this map

  1. Breast cancer · Nadia Harbeck · 2019 · 3072 citations · Cited by this paper
  2. Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer · 2026 · Related
  3. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer · Joseph A. Sparano · 2018 · 2448 citations · Cited by this paper
  4. Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females · 2026 · Related
  5. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years · Hongchao Pan · 2017 · 1889 citations · Cited by this paper
  6. Effect of Treatment Sequencing in Older Adults With Early Breast Cancer. Insights From a Retrospective Single-Institution Cohort · 2026 · Related
  7. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline · Larissa A. Korde · 2021 · 1058 citations · Cited by this paper
  8. Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping · 2026 · Related
  9. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer · Kevin Kalinsky · 2021 · 889 citations · Cited by this paper
  10. Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care · 2026 · Related
  11. Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics · Michael J. Ellis · 2008 · 668 citations · Cited by this paper
  12. Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer · 2026 · Related
  13. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial · Ian Smith · 2020 · 330 citations · Cited by this paper
  14. Association of Regional Anesthesia With Reduced Post-discharge Opioid Prescriptions Following Immediate Autologous Breast Reconstruction: An ACS-NSQIP Analysis · 2026 · Related
  15. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype · Amy E. McCart Reed · 2021 · 197 citations · Cited by this paper
  16. Evaluation of Absorbable Hemostatic Powder on Post-operative Outcomes in Patients Undergoing Mastectomy · 2026 · Related
  17. Tamoxifen · Micaela M.-T. Buckley · 1989 · 167 citations · Cited by this paper
  18. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer · Ulrike A. Nitz · 2022 · 145 citations · Cited by this paper
  19. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data · Amila Orucevic · 2019 · 85 citations · Cited by this paper
  20. Neoadjuvant Endocrine Therapy in Clinical Practice · Tal Sella · 2021 · 63 citations · Cited by this paper
  21. Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis · Kamila Boszkiewicz · 2022 · 54 citations · Cited by this paper
  22. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy · Jeremy P. Braybrooke · 2025 · 38 citations · Cited by this paper
  23. Artificial intelligence-assisted interpretation of Ki-67 expression and repeatability in breast cancer · Lina Li · 2022 · 32 citations · Cited by this paper
  24. Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours · Cornelia M. Focke · 2016 · 31 citations · Cited by this paper
  25. Concordance between core needle biopsy and surgical excision specimens for Ki‐67 in breast cancer – a systematic review of the literature · Jahnavi Kalvala · 2021 · 23 citations · Cited by this paper
  26. The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study · Covadonga Martí · 2022 · 21 citations · Cited by this paper
  27. Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance · Soraia Lobo-Martins · 2025 · 20 citations · Cited by this paper
  28. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) · Judith M. Bliss · 2023 · 19 citations · Cited by this paper
  29. ER-positive and BRCA2-mutated breast cancer: a literature review · Pu‐Chun Li · 2024 · 17 citations · Cited by this paper
  30. Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature · Sara Christensen Holz · 2023 · 14 citations · Cited by this paper
  31. Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use · Nicole Margo Grogan Fleege · 2023 · 12 citations · Cited by this paper
  32. Side-effects in women treated with adjuvant endocrine therapy for breast cancer · Lee Rademaker · 2025 · 12 citations · Cited by this paper
  33. Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining · Benjamin Frederik Dessauvagie · 2019 · 10 citations · Cited by this paper
  34. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature · Josefien P. van Olmen · 2024 · 8 citations · Cited by this paper
  35. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting · Joseph Do Woong Choi · 2022 · 7 citations · Cited by this paper
  36. Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk · Volkmar Müller · 2025 · 5 citations · Cited by this paper
  37. Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study · Milana A. Bergamino · 2025 · 5 citations · Cited by this paper
  38. Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy · R Gómez-Bravo · 2025 · 5 citations · Cited by this paper
  39. Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer · Evelyn Klein · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)